<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594994</url>
  </required_header>
  <id_info>
    <org_study_id>201805183</org_study_id>
    <nct_id>NCT03594994</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Sleep Extension in People With Obesity</brief_title>
  <official_title>Metabolic Effects of Sleep Extension in People With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the impact of extending sleep duration on glucose
      metabolism in people with obesity. Half of the participants will be instructed to increase
      their time-in-bed to 8 hours (sleep extension) while the other half will be be instructed to
      maintain their current sleep habits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Restricting sleep is known to be detrimental to glucose metabolism in healthy adults. Obesity
      is a condition associated with both lower sleep duration and poor glucose tolerance.
      Therefore, increasing sleep duration is a potentially novel therapeutic strategy for
      improving glucose metabolism in this population. The investigators will assess this by
      determining insulin sensitivity during a hyperinsulinemic-euglycemic clamp before and after a
      sleep extension intervention in both the control and sleep extension groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>Change from baseline testing after 4-6 weeks of intervention</time_frame>
    <description>Whole-body insulin sensitivity during a hyperinsulinemic-euglycemic clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour metabolite concentrations</measure>
    <time_frame>Change from baseline testing after 4-6 weeks of intervention</time_frame>
    <description>Plasma metabolite concentrations will be evaluated over a 24 hour period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour hormone concentrations</measure>
    <time_frame>Change from baseline testing after 4-6 weeks of intervention</time_frame>
    <description>Plasma hormone concentrations will be evaluated over a 24 hour period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour cytokine concentrations</measure>
    <time_frame>Change from baseline testing after 4-6 weeks of intervention</time_frame>
    <description>Plasma cytokine concentrations will be evaluated over a 24 hour period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>regulation of circadian rhythm</measure>
    <time_frame>Change from baseline testing after 4-6 weeks of intervention</time_frame>
    <description>Expression of peripheral clock genes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Change from baseline testing after 4-6 weeks of intervention</time_frame>
    <description>Body composition will be assessed using dual-energy x-ray absorptiometry (DXA) and magnetic resonance scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep study</measure>
    <time_frame>Change from baseline testing after 4-6 weeks of intervention</time_frame>
    <description>Sleep staging will be assessed during an inpatient sleep study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normal sleep habits &lt; 6h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleep Extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extend time-in-bed to 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sleep extension</intervention_name>
    <description>Extend time-in-bed to 8 hours</description>
    <arm_group_label>Sleep Extension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sleep &lt;6h/night

          -  Body mass index 30-45 kg/m2

          -  Altered glucose metabolism (any of the following) Fasting glucose ≥100 mg/dL or, 2-h
             plasma glucose ≥140 mg/dL during an oral glucose tolerance test (OGTT) or, HbA1c ≥5.7%
             or, homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.5

        Exclusion Criteria:

          -  Sleep disorders

          -  Excessive caffeine or alcohol consumption

          -  Significant organ dysfunction/disease (e.g. diabetes, kidney disease)

          -  Prior bariatric surgery

          -  Pregnancy

          -  Tobacco or illicit drug use

          -  Perform regular moderate or intense exercise
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>314-273-1882</phone>
    <email>bogerz@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph Beals</last_name>
    <phone>314-362-8199</phone>
    <email>bealsjw@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <phone>314-273-1882</phone>
      <email>bogerz@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Beals</last_name>
      <phone>3143628199</phone>
      <email>bealsjw@wustl.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

